2024
Discordance Between Insurance Coverage of Antiviral Medications and Nicotine Replacement Therapy Among Individuals With Human Immunodeficiency Virus Who Smoke
Bernstein S, Yager J, Sigel K, Porter E, Do T, Payne E, Bold K, Ledgerwood D, Edelman E. Discordance Between Insurance Coverage of Antiviral Medications and Nicotine Replacement Therapy Among Individuals With Human Immunodeficiency Virus Who Smoke. Journal Of Addiction Medicine 2024, 18: 404-407. PMID: 38606851, PMCID: PMC11290992, DOI: 10.1097/adm.0000000000001302.Peer-Reviewed Original ResearchNicotine replacement therapyHuman immunodeficiency virusTobacco use disorderAntiretroviral therapyReplacement therapyTobacco useImmunodeficiency virusCoverage of antiretroviral therapyInsurance coverageSecondary analysis of dataUse disorderManaged care planOut-of-pocketMandated insurance coverageCare planningEfficacy of antiviralsRandomized clinical trialsPharmacy benefit managersInsurance barriersMedication prescriptionsSecondary analysisTracking formParticipation AssessmentAntiviral medicationsPWH
2023
Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT
Justen M, Scodes J, Pavlicova M, Choo T, Gopaldas M, Haeny A, Opara O, Rhee T, Rotrosen J, Nunes E, Hawk K, Edelman E. Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT. Journal Of Addiction Medicine 2023, 17: 463-467. PMID: 37579110, PMCID: PMC10323031, DOI: 10.1097/adm.0000000000001125.Peer-Reviewed Original ResearchConceptsClinical trialsTreatment outcomesSecondary analysisOpioid use disorder treatmentBlack individualsExtended-release naltrexoneOpioid use disorderAdditional clinical supportBlack participantsUse disorder treatmentBuprenorphine-naloxoneStudy medicationWeeks postrandomizationMedication initiationClinical characteristicsOpioid useTrial entryUrine toxicologyBlack patientsSedative useExtramedical useUse disordersClinical supportDisorder treatmentBlack adults